Dokument-ID Dokumenttyp Verfasser/Autoren Herausgeber Haupttitel Abstract Auflage Verlagsort Verlag Erscheinungsjahr Seitenzahl Schriftenreihe Titel Schriftenreihe Bandzahl ISBN Quelle der Hochschulschrift Konferenzname Quelle:Titel Quelle:Jahrgang Quelle:Heftnummer Quelle:Erste Seite Quelle:Letzte Seite URN DOI Abteilungen OPUS4-2355 Dissertation Diwischek, Florian Development of synthesis pathways and characterization of cerulenin analogues as inhibitors of the fatty acid biosynthesis of Mycobacterium tuberculosis and of efflux pump resistant Candida albicans The work deals with the synthesis and characterization of cerulenin analogues as inhibitors of efflux pump mediated resistance of Candida albicans isolates and as inhibitors of the fatty acid synthesis enzyme KasA of Mycobacterium tuberculosis. Cerulenin was chosen as the lead structure, being a substrate of the efflux pumps in Candida albicans on one hand and therefore variations on the structure could lead to a blocking of the efflux pumps as in the case of tetracycline and inhibitor 13-CPTC of the TetB efflux pump. On the other hand, cerulenin is a known inhibitor of the FAS system but inhibition is unselective in type I and II FAS. Therefore, analogues could result in increased selectivity towards the type II FAS system in M. tuberculosis. The first cerulenin derivatives were prepared by coupling 2,3-dihydrofuran to the before synthesized 1-octaniodide, followed by ring opening and oxidation in one step by chromic acid and transfer of the resulting 4-keto acid to amides to give analogues 4a-d, 4e was prepared in analogy. To include the epoxide function especially with regard to the mechanism of action of cerulenin in the FAS system (considering known crystal structures of cerulenin and the KasA analogue of E. coli) tetrahydro- and dihydrocerulenin analogues were synthesized. Starting from the corresponding aldehyde, lactone 5 (tetrahydrocerulenin analogues) was obtained via two different routes A and B. Route A included the coupling of the aldehyde 1-nonanal to propiolic acid via a Grignard reaction with subsequent hydrogenation with the Lindlar catalyst under hydrogen pressure to give 5. Via Route B 1-nonanal was coupled to methyl propiolate by n-BuLi with subsequent hydrogenation under reflux with the catalytic system Lindlar cat./NH4HCO2 to yield 5. These hydrogenations were also executed in a microwave oven resulting in better yields and/or reaction times. The lactone 5 was then epoxidized, the ring opened by amidation and the remaining alcohol was oxidized via Collins oxidation to result in tetrahydrocerulenin analogues 8a-e. The same procedure was used for dihydrocerulenin analogues 10a-c except that to obtain the corresponding lactone 9a only route A was used and a further step had to be executed for ring closure. To obtain analogues with all structural features of cerulenin including two double bonds and the epoxide function, a third pathway was chosen. To obtain the future side chain, aldehyde 12 was synthesized by coupling protected 4-pentyn-1-ol to either crotyl bromide or crotyl chloride, which then was deprotected, hydrogenated with Lindlar catalyst under hydrogen pressure and oxidized via a Swern oxidation. The following synthesis sequence starting from 12 was executed similar to that of dihydrocerulenins via the corresponding lactone (51) with the major exception of the oxidation procedure in the last step via TPAP/NMO to result in (4Z,7E)-cerulenin analogues 15a-b. A fourth class of cerulenin analogues was synthesized with the aromatic analogues 17a-e. This synthesis pathway started with the formation of the benzoyl acrylamides 16a-e from benzoylacrylic acid via a mixed anhydride which was prepared with isobutylchloroformate followed by the addition of the corresponding amine. Subsequent epoxidation with H2O2 in basic EtOH gave the aromatic cerulenin analogues 17a-e. Pharmacological testings for the synthesized substances were executed on efflux pump-resistant and -sensitive Candida albicans isolates, on the fatty acid synthesis enzyme KasA of Mycobacterium tuberculosis and on other organisms such as Leishmania major, Trypanosoma brucei brucei, Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Pseudomonas aeruginosa within the Sonderforschungsbereich 630. 2008 urn:nbn:de:bvb:20-opus-27532 Institut für Pharmazie und Lebensmittelchemie